Ritter Pharmaceuticals (RTTR) Getting Somewhat Favorable News Coverage, Analysis Shows

News headlines about Ritter Pharmaceuticals (NASDAQ:RTTR) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ritter Pharmaceuticals earned a media sentiment score of 0.04 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.8643823199245 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the news headlines that may have effected Accern’s rankings:

How to Become a New Pot Stock Millionaire

Shares of Ritter Pharmaceuticals (NASDAQ RTTR) traded down $0.01 on Monday, hitting $3.07. The stock had a trading volume of 356,228 shares, compared to its average volume of 77,130. Ritter Pharmaceuticals has a 52 week low of $1.80 and a 52 week high of $20.30.

A number of research firms have issued reports on RTTR. Zacks Investment Research cut Ritter Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, December 26th. ValuEngine upgraded Ritter Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $13.75.

ILLEGAL ACTIVITY WARNING: This news story was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.tickerreport.com/banking-finance/3303094/ritter-pharmaceuticals-rttr-getting-somewhat-favorable-news-coverage-analysis-shows.html.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Insider Buying and Selling by Quarter for Ritter Pharmaceuticals (NASDAQ:RTTR)

Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

WavesGo Price Hits $0.0298 on Major Exchanges
WavesGo Price Hits $0.0298 on Major Exchanges
DFSCoin Reaches Market Cap of $780,834.00
DFSCoin Reaches Market Cap of $780,834.00
Ceconomy  and GNC  Critical Survey
Ceconomy and GNC Critical Survey
Head to Head Contrast: CSG Systems International  and Mindbody
Head to Head Contrast: CSG Systems International and Mindbody
China Life Insurance  versus Its Rivals Head to Head Analysis
China Life Insurance versus Its Rivals Head to Head Analysis
Analysts Expect BeiGene  Will Post Earnings of -$1.96 Per Share
Analysts Expect BeiGene Will Post Earnings of -$1.96 Per Share


© 2006-2018 Ticker Report. Google+.